Breaking News
Subscribe Now 0
👀 Ones to watch: Undervalued stocks to buy before they report Q3 earnings See Undervalued Stocks
Close

Kiniksa Pharmaceuticals Ltd (KNSA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Kiniksa Pharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
27.02 +0.39    +1.45%
15:06:29 - Real-time Cboe. Currency in USD
Type:  Equity
Market:  United States
  • Volume: 132,386
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 26.41 - 27.18
Kiniksa Pharma 27.02 +0.39 +1.45%

Kiniksa Pharma (KNSA) Earnings Dates & Reports

 
On this page, you can find detailed information about the financial performance of Kiniksa Pharmaceuticals Ltd, including the latest Kiniksa Pharmaceuticals Ltd earnings report and upcoming earnings date. The page provides an overview of the company's financial health, with key data points such as the current stock price, earnings per share, and revenue compared against the forecast.
Earnings Insights
Latest Release

Jul 23, 2024

EPS / Forecast

-0.06 / -0.08

Revenue / Forecast

108.63M / 90.6M

Revenue
EPS
 Forecast
 
Release Date Period End EPS /  Forecast Revenue /  Forecast
Feb 26, 2025 12/2024 -- /  0.08 -- /  122.38M
Oct 28, 2024 09/2024 -- /  0.03 -- /  110.29M
Jul 23, 2024 06/2024 -0.06 /  -0.08 108.63M /  90.6M
Apr 23, 2024 03/2024 -0.25 /  -0.14 79.86M /  76.97M
Feb 28, 2024 12/2023 0.35 /  -0.11 83.4M /  72.36M
Oct 31, 2023 09/2023 -0.2 /  -0.17 67.05M /  64.55M
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View upcoming earnings forecasts and in-depth analysis of company forecasts.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

KNSA Comments

Write your thoughts about Kiniksa Pharmaceuticals Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Stephen Appiah
Stephen Appiah Mar 19, 2021 9:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I'm surprised no activity there is little activity on this stock.
Arl Nn
ArlN Mar 18, 2021 5:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The FDA has approved. - ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis- Commercial launch expected in April 2021- Kiniksa launches Kiniksa One Connect™ patient support program
Arl Nn
ArlN Mar 15, 2021 6:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Breakthrough Therapy designation granted by the FDA for rilonacept for the treatment of recurrent pericarditis, due date is 21st March 2021 under priority review.That should help some movement
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email